Key takeaways
- Lancôme has launched its first longevity‑focused skincare range developed with Swiss biotech Timeline.
- The range introduces Mitopure® (Urolithin A) into topical beauty for the first time.
- The molecule targets the skin’s biological age through mitophagy‑driven cellular renewal.
- The launch signals Lancôme’s broader push into longevity science and precision beauty diagnostics.
- The new range will debut at the 2026 American Academy of Dermatology Annual Meeting.
L’Oréal brand Lancôme has created a new longevity‑based skincare range developed with Swiss longevity biotech firm Timeline. It is the first consumer launch produced in partnership since L’Oréal Groupe invested in the company in 2024.
The range, which will be unveiled at the American Academy of Dermatology (AAD) Annual Meeting from 27–29 March, introduces Mitopure (Urolithin A) into topical skincare.
Bringing longevity biotechnology into mainstream skincare
The clinically studied longevity molecule, derived from pomegranate ellagitannins, has previously been used in oral longevity‑focused supplements. It is designed to act on the skin’s biological age rather than deliver short‑term cosmetic effects.
For Lancôme, the launch signals a move to translate longevity science into consumer beauty at scale, bringing a category that has largely remained niche within supplements and wellness clinics into mainstream skincare.
Mitopure: the molecule powering Lancôme’s new range
Mitopure is a proprietary molecule backed by more than $50 million in R&D and 15 years of research, is a highly pure form of Urolithin A — a postbiotic clinically proven to re‑energise mitochondria, the powerhouses of the cell, through a renewal process known as mitophagy.
According to Vania Lacascade, Global Brand President of Lancôme, longevity is a frontier of radical progress, not a matter of appearance. “We are defining a new scientific era where beauty is proactive, decoding the core biological mechanisms of skin aging,” she said. “By orchestrating meaningful partnerships with the world’s most advanced biotech innovators – like Timeline and its Mitopure® molecule – we are accelerating our mission to pioneer high-performance solutions. Our goal is to shift the conversation on aging, using cutting-edge science to restore cellular vitality and offer women a new perspective on their own skin’s trajectory.”
Meanwhile, Chris Rinsch, co-founder and President of Timeline, said the collaboration marks an exciting new chapter for the company. “This partnership presents a remarkable opportunity to democratise our longevity molecule, Mitopure®, making its advanced skin benefits more widely accessible than ever,” he said.
Lancôme’s growing focus on cellular ageing and skin healthspan
Lancôme believes this chapter represents a major scientific breakthrough, opening a new societal paradigm that is no longer about masking the signs of time but decoding the fundamental biological mechanisms to preserve and restore skin healthspan.
The brand has recently placed greater emphasis on longevity science. In 2025, it introduced Absolue Longevity The Soft Cream, powered by patent‑pending Absolue PDRN™. Known to augment cell longevity metabolism, it adds to Lancôme’s Absolue Longevity The Soft Cream’s demonstrated ability to reverse visible signs of ageing layer by layer.
Last year, the company also showcased its Precision Beauty Tech (Cell BioPrint™). Through a partnership with Korean start‑up NanoEnTek, Lancôme developed a first‑of‑its‑kind “lab‑on‑chip” skin analysis solution. Using proteomics and microfluidics to analyse skin‑surface protein biomarkers, Cell BioPrint™ determines the biological age of the skin surface and models future skin‑beauty longevity trajectories. This enables a shift from reactive correction to proactive, data‑driven care.
The new Lancôme longevity skincare range, Mitopure® by Timeline®, will be revealed at the annual American Academy of Dermatology (AAD) convention in Denver, Colorado, from 27 to 29 March 2026.